Loading
A phase 2 trial of Eganelisib run by Infinity Pharmaceuticals, Inc., completed.
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) is a phase 2 interventional study registered as NCT03980041 by Infinity Pharmaceuticals, Inc., with 49 participants enrolled, started 2019-09-25. Conditions recorded: Bladder Cancer, Urothelial Carcinoma, Solid Tumor and Advanced Cancer. Interventions recorded: IPI-549 (eganelisib), Nivolumab and Placebos.
Shares Stelexis BioSciences, Eganelisib and the tag pipeline.
Shares Stelexis BioSciences, Eganelisib and the tag pipeline.
Shares Stelexis BioSciences, Eganelisib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/